Imaging scan to track immunotherapy response in advanced soft tissue sarcoma
Tests a PET scan tracer to see if it predicts immunotherapy success in advanced sarcoma.
Plain-language title generated from the registry record
Registry title: The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 80 years old?
Source: NCT06644287, who can take part
Where in China
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06644287
- Record updated
- 13 December 2024
- Original description
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.Read full original descriptionShow less
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.
Inclusion: Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma; Consider immunotherapy or combined immunotherapy based on clinical judgement; Signed and dated informed consent form; Commitment to comply with research procedures and co-operation in the implementation of the full research process; Aged 6-80 years old.
Exclusion: Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc; Intestinal perforation, complete intestinal obstruction; Pregnant women and women who may be pregnant, women who are breastfeeding; Non-compliant person.